Proteomics has illuminated disease pathophysiology, unearthed novel biomarkers, and bolstered risk assessment strategies. In nephrology, observational analyses unveil biomarkers associated with adverse outcomes, whereas genetics offer insights into causal pathways. Mendelian randomization offers the potential to link the two, uncovering causal relationships between biomarkers and kidney function. Lanktree et al. demonstrate Mendelian randomization's utility in identifying additional proteins affecting kidney function and kidney disease progression.